478832-21-2

Basic information

• Product Name: 4-HYDROXYAZEPANE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: N-BOC-HEXAHYDRO-1H-AZEPIN-4-OL;1H-AZEPINE-1-CARBOXYLIC ACID, HEXAHYDRO-4-HYDROXY-, 1,1-DIMETHYLETHYL ESTER;4-HYDROXYAZEPANE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-HYDROXYAZEPANE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, 95+%;1-Boc-Hexahydro-1H-azepin-4-ol;1-Boc-Hexahydro-1H-azepin...;1-Boc-4-Hydroxyazepane;4-hydroxy-1-azepanecarboxylic acid tert-butyl ester
• CAS NO: 478832-21-2
• Molecular Formula: C₁₁H₂₁NO₃
• Molecular Weight: 215.29
• Mol File: 478832-21-2.mol

Chemical Properties

• Boiling Point: 310.6 °C at 760 mmHg
• Flash Point: 141.7 °C
• Appearance: /
• Density: 1.079 g/cm³
• Vapor Pressure: 5.3E-05mmHg at 25°C
• Refractive Index: 1.489
• Storage Temp.: 2-8°C
• PKA: 15.06±0.20(Predicted)
• CAS DataBase Reference: 4-HYDROXYAZEPANE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXYAZEPANE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(478832-21-2)
• EPA Substance Registry System: 4-HYDROXYAZEPANE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(478832-21-2)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 478832-21-2(Hazardous Substances Data)

Usage

Uses

Used in Research Applications:
4-Hydroxyazepane-1-carboxylic Acid Tert-Butyl Ester is used as a research compound for its complex molecular structure, which allows for various synthetic and chemical reactions. Its reactivity with strong acids or bases makes it a valuable tool in the development of new chemical processes and products.
Used in Pharmaceutical Industry:
4-Hydroxyazepane-1-carboxylic Acid Tert-Butyl Ester is used as a synthetic intermediate for the development of pharmaceutical compounds. Its unique structure and reactivity contribute to the creation of new drug candidates with potential therapeutic applications.
Used in Chemical Synthesis:
4-Hydroxyazepane-1-carboxylic Acid Tert-Butyl Ester is used as a key component in the synthesis of various organic compounds. Its versatility in undergoing hydrolysis and other chemical reactions makes it an essential building block in the production of specialty chemicals and materials.

InChI:InChI=1/C11H21NO3/c1-11(2,3)15-10(14)12-7-4-5-9(13)6-8-12/h9,13H,4-8H2,1-3H3

Upstream product

• 109162-29-0 1-benzyl-4-hydroxyhexahydro-1H-azepine 
• 1208-75-9 1-benzylazepan-4-one 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 34619-03-9 tert-butyldicarbonate 
• 188975-88-4 tert-butyl 4-oxoazepane-1-carboxylate 
• 39888-51-2 azepan-4-ol 
• 1208-76-0 1-benzyl-1,2,3,5,6,7-hexahydroazepine-4-one hydrochloride 

Downstream Products

• 1103500-50-0 4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]azepane-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Interrupting the Barton?McCombie reaction: Aqueous deoxygenative trifluoromethylation of o-alkyl thiocarbonates

The site-selective trifluoromethylation of aliphatic systems remains an important challenge. This work describes a light-driven, copper-mediated trifluoromethylation of O-alkyl thiocarbonates. The reaction provides broad functional group tolerance (e.g., alkyne, alkene, phenol, free alcohol, electron-rich and -deficient arenes), thereby offering orthogonality and practicality for trifluoromethylation. A radical organometallic mechanism is proposed.

SUBSTITUTED (AZA)INDOLE DERIVATIVES

The invention relates to substituted (aza)indole derivatives, or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof, as well as to pharmaceutical compositions containing them and to their use as modulators of α7 nicotinic acetylcholine receptor activity in a mammalian subject. (I)

Stereo-complementary bioreduction of saturated N-heterocyclic ketones

The asymmetric bioreduction of several saturated N-heterocyclic ketones is demonstrated in a stereo-complementary fashion using the ketoreductases READH and ChKRED20 for the production of (S)- and (R)-alcohols, respectively. The reaction accepts substrates with a five-, six- or seven-membered ring, and exhibits excellent stereoselectivity when using 2-propanol as both the ultimate reducing agent and cosolvent, achieve >99% ee in the majority of cases for both enantiomers.

12-EPI PLEUROMUTILINS

A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.

12-EPI-PLEUROMUTILINS

A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-0-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula PLEU, processes for the preparation of such compounds and their use as pharmaceuticals.

Antibacterial homopiperidinyl substituted 3,4 dihydro 1H[1,8]naphthyridinones

The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

ANTIBACTERIAL HOMOPIPERIDINYL SUBSTITUTED 3,4 DIHYDRO 1H [1,8]NAPHTHYRIDINONES

The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.

PRIMARY AMINE DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES

A compound having the structure useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.

TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS

Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.

COMPOUNDS AND METHODS FOR MODULATING FXR

Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.